Endometrial Cancer: Faina Linkov, PHD Research Assistant Professor University of Pittsburgh Cancer Institute
Endometrial Cancer: Faina Linkov, PHD Research Assistant Professor University of Pittsburgh Cancer Institute
Endometrial Cancer: Faina Linkov, PHD Research Assistant Professor University of Pittsburgh Cancer Institute
• Diagnosis • Treatment
– Pelvic examination – Surgery
– Pap smear (detect cancer • Hysterectomy
spread to cervix)
• Salpingo-oophorectomy
– Endometrial biopsy
• Pelvic lymph node
– Dilation and curettage dissection
– Transvaginal ultrasound • Laparoscopic lymph node
sampling
– Radiation therapy
– Chemotherapy
– Hormone therapy
• Progesterone
• Tamoxifen
Endometrial hyperplasia
• Overgrowth of the glandular epithelium of
the endometrial lining
• Usually occurs when a patient is exposed
to unopposed estrogen, either
estrogenically or because of anovulation
• Rates of neoplasm
– simple hyperplasia: 1%.
– complex hyperplasia with atypia: 30%
Endometrial Hyperplasia
• Complex hyperplasia with atypia
– One study found incidence of concomitant
endometrial cancer in 40% of cases
– Hysterectomy or high dose progestin tx
• Simple
– Often regress spontaneously
– Progestin treatment used for treating bleeding
may help in treating hyperplasia as well
• Estrogen dependent disease
– Prolonged exposure without the balancing effects
of progesterone
• Premalignant potential
– Endometrial hyperplasia
– Simple => 1%
– Complex => 3%
– Simple with atypia => 8%
– Complex with atypia => 29%
Reduced Risk
• Oral Contraceptives
– Combined OC => 50% reduced rate
– Actual reduction number small because
uncommon in women of child bearing age
– Long term offers protection
– Reduced risk presumably => progesterone
• Tobacco Smoking
– Some evidence that it reduces the rate
– Smokers have lower levels of estrogen and lower
rate of obesity
Prevention and Survival
• Early detection is best prevention
• Treating precancerous hyperplasia
– Hormones (progestin)
– D&C
– Hysterectomy
– 10 ~ 30% untreated develop into cancer
• Average 5 year survival
– Stage I => 72 ~ 90%
– Stage II=> 56 ~ 60%
– Stage III => 32 ~ 40%
– Stage IV => 5 ~ 11%
Potentially modifiable risk factors
Dietary factors
Isoflavones:
Phytoestrogens that
have properties
similar to selective
estrogen receptor
modulators